Search

Your search keyword '"Cortelazzo S"' showing total 102 results
Start Over Author "Cortelazzo S" Database OpenAIRE
102 results on '"Cortelazzo S"'

1. P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL

Author

Alessandria, B., Genuardi, E., Civita, A. M., Drandi, D., Mantoan, B., Ferrante, M., Borriero, M., Ragaini, S., Bondielli, G., Zaccaria, G. M., Barbero, D., Peri, V., Hohaus, S., Musuraca, G., Cascavilla, N., Ghiggi, C., Tani, M., Gaidano, G., Volpetti, S., Usai, S. V., Di Renzo, N., Cortelazzo, S., Ladetto, M., and Ferrero, S.

Subjects
Hematology
Published
2022
Full Text
View/download PDF

3. PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Author

Caprioli, C, Spinelli, O, Salmoiraghi, S, Intermesoli, T, Zanghi, P, Cavagna, R, Michelato, A, Buklijas, K, Elidi, L, Delaini, F, Oldani, E, Gianfaldoni, G, Bosi, A, Marmont, F, Audisio, E, Ferrero, D, Terruzzi, E, De Paoli, L, Rossi, G, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, Am, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Cortelazzo, S, Falini, B, Pavoni, C, Bassan, R, Rambaldi, A, and Lussana, F

Published
2019

4. MOLECULAR PROLIFE BY NEXT GENERATION SEQUENCING OF ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: CLINICAL RESULTS FROM THE PROSPECTIVE TRIAL 02/06 OF THE NORTHERN ITALY LEUKEMIA GROUP (NILG)

Author

Spinelli, O, Salmoiraghi, S, Zanghi, P, Cavagna, R, Michelato, A, Buklijas, K, Zannino, L, Intermesoli, T, Lussana, F, Delaini, F, Oldani, E, Caprioli, C, Stefanoni, P, Gianfaldoni, G, Marmont, F, Ferrero, D, Terruzzi, E, De Paoli, L, Rossi, G, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, Am, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Cortelazzo, S, Audisio, E, Bosi, A, Falini, B, Pavoni, C, Bassan, R, and Rambaldi, A

Published
2018

5. Treosulfan-fludarabine-ATG-F based reduced-toxicity conditioning regimen: multicentre 'Allo-Treo' study, results in 183 patients with haematological malignancies

Author

Crotta A, Lorusso A, Martinelli G, Cortelazzo S, Pinazzi MB, La Nasa G, Foa R, Santarone S, Rambaldi A, Gallamini A, Fanin R, Merli F, Carella AM, Corti C, Ruggeri A, Marcatti M, Stanghellini MTL, Assanelli A, Messina C, Bernardi M, Peccatori J., CICERI , FABIO, Crotta, A, Lorusso, A, Martinelli, G, Cortelazzo, S, Pinazzi, Mb, La Nasa, G, Foa, R, Santarone, S, Rambaldi, A, Gallamini, A, Fanin, R, Merli, F, Carella, Am, Corti, C, Ruggeri, A, Marcatti, M, Stanghellini, Mtl, Assanelli, A, Messina, C, Bernardi, M, Ciceri, Fabio, and Peccatori, J.

Published
2012

6. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma

Author

Cavo, Michele, Pantani, Lucia, Petrucci, Maria Teresa, Patriarca, Francesca, Zamagni, Elena, Donnarumma, Daniela, Crippa, Claudia, Boccadoro, Mario, Perrone, Giulia, Falcone, Antonietta, Nozzoli, Chiara, Zambello, Renato, Masini, Luciano, Furlan, Anna, Brioli, Annamaria, Derudas, Daniele, Ballanti, Stelvio, Dessanti, Maria Laura, De Stefano, Valerio, Carella, Angelo Michele, Marcatti, Magda, Nozza, Andrea, Ferrara, Felicetto, Callea, Vincenzo, Califano, Catello, Pezzi, Annalisa, Baraldi, Anna, Grasso, Mariella, Musto, Pellegrino, Palumbo, Antonio COLLABORATORI: Tosi, P, Motta, Mr, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, Franco, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, Mc, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, Am, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, Mc, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E., Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A., Cavo, Michele, Pantani, Lucia, Petrucci, Maria Teresa, Patriarca, Francesca, Zamagni, Elena, Donnarumma, Daniela, Crippa, Claudia, Boccadoro, Mario, Perrone, Giulia, Falcone, Antonietta, Nozzoli, Chiara, Zambello, Renato, Masini, Luciano, Furlan, Anna, Brioli, Annamaria, Derudas, Daniele, Ballanti, Stelvio, Dessanti, Maria Laura, De Stefano, Valerio, Carella, Angelo Michele, Marcatti, Magda, Nozza, Andrea, Ferrara, Felicetto, Callea, Vincenzo, Califano, Catello, Pezzi, Annalisa, Baraldi, Anna, Grasso, Mariella, Musto, Pellegrino, Palumbo, Antonio, Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, and Quartarone, E

Subjects
Male, Boronic Acid, medicine.medical_treatment, PLUS DEXAMETHASONE, Phases of clinical research, Kaplan-Meier Estimate, Hematopoietic stem cell transplantation, Biochemistry, Antineoplastic Agent, Bortezomib-thalidomide-dexamethasone, Bortezomib, Immunosuppressive Agent, Autologous stem-cell transplantation, MULTIPLE MYELOMA, Antineoplastic Combined Chemotherapy Protocols, thalidomide-dexamethasone, Multiple myeloma, RANDOMIZED PHASE-3, LENALIDOMIDE, STEM CELL TRANSPLANTATION, Hematopoietic Stem Cell Transplantation, PHASE-III TRIAL, Hematology, Middle Aged, CHEMOTHERAPY, Prognosis, Boronic Acids, Combined Modality Therapy, Thalidomide, Transplantation, Autologou, Pyrazines, HIGH-DOSE MELPHALAN, INDUCTION TREATMENT, Female, Autologous, Immunosuppressive Agents, Pyrazine, Human, medicine.drug, MAINTENANCE THERAPY, medicine.medical_specialty, DOXORUBICIN, Antineoplastic Agents, Hormonal, Prognosi, Immunology, Urology, Antineoplastic Agents, dexamethasone, Transplantation, Autologous, Disease-Free Survival, Dexamethasone, Humans, Multiple Myeloma, Cell Biology, medicine, Autologous transplantation, METAANALYSIS, Transplantation, Antineoplastic Combined Chemotherapy Protocol, Hormonal, business.industry, medicine.disease, Surgery, business, Settore MED/15 - Malattie del Sangue
Abstract

In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.

Published
2012

8. High-dose sequential chemoimmunotherapy supported by autologous stem cell transplantation in patients with systemic B-cell lymphoma and central nervous system involvement: interim analysis of a multicentre phase II Trial

Author

Marturano E, Patti C, Cabras MG, Cortelazzo S, Zambello R, Carrabba M, Mule A, Peccatori J, Tarella C, Ferreri AJ, CICERI , FABIO, Marturano, E, Patti, C, Cabras, Mg, Cortelazzo, S, Zambello, R, Carrabba, M, Mule, A, Peccatori, J, Ciceri, Fabio, Tarella, C, and Ferreri, Aj

Published
2011

9. Factors influencing the occurrence of secondary malignancies in high-risk lymphoma patients following high-dose therapy and autograft

Author

Tarella C, Passera R, Magni M, Rossi A, Benedetti F, Gueli A, Ruella M, Patti C, Parvis G, Gallamini A, Cortelazzo S, Corradini P, Zoli V, Mule A, Crocchiolo R, Bosa M, Barbui A, Di Nicola M, Caracciolo D, Sorio M, Gianni AM, Rambaldi A., CICERI , FABIO, Tarella, C, Passera, R, Magni, M, Rossi, A, Benedetti, F, Gueli, A, Ruella, M, Patti, C, Parvis, G, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Corradini, P, Zoli, V, Mule, A, Crocchiolo, R, Bosa, M, Barbui, A, Di Nicola, M, Caracciolo, D, Sorio, M, Gianni, Am, and Rambaldi, A.

Published
2010

10. Allogeneic Stem Cell Transplantation (Allo-SCT) Following a Reduced-Intensity Conditioning (RIC) Regimen in Relapsed Peripheral T-Cell Lymphomas (PTCL): Results at 4 Year of Median Follow-up

Author

Dodero A, Spina F, Nami F, Patriarca F, Cortelazzo S, Benedetti F, CICERI , FABIO, Baronciani D, Scime' R, Pogliani E, Rambaldi A, Bonifazi F, Olivieri A, Bruno B, Tarella C, Corradini P., Dodero, A, Spina, F, Nami, F, Patriarca, F, Cortelazzo, S, Benedetti, F, Ciceri, Fabio, Baronciani, D, Scime', R, Pogliani, E, Rambaldi, A, Bonifazi, F, Olivieri, A, Bruno, B, Tarella, C, and Corradini, P.

Published
2009

11. TIME OF PERIPHERAL BLOOD PROGENITOR CELL COLLECTIONS MAY INFLUENCE THE RISK OF SECONDARY MYELODYSPLASTIC SYNDROME/ACUTE LEUKEMIA FOLLOWING INTENSIVE THERAPY AND AUTOGRAFT: A GITIL SURVEY ON 1,347 LYMPHOMA PATIENTS RECEIVING THE HIGH-DOSE SEQUENTIAL PROGRAM

Author

Tarella C, Zanni M, Magni M, Rossi A, Benedetti F, Passera R, Patti C, Parvis G, Gallamini A, Cortelazzo S, Majolino I, Barbui T, Mirto S, Corradini P, Boccadoro M, Saglio G, Pizzolo G, Rambaldi A, Gianni AM, CICERI , FABIO, Tarella, C, Zanni, M, Magni, M, Rossi, A, Benedetti, F, Passera, R, Patti, C, Parvis, G, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Barbui, T, Mirto, S, Corradini, P, Boccadoro, M, Saglio, G, Pizzolo, G, Rambaldi, A, and Gianni, Am

Published
2008

12. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage

Author

Ladetto, M, DE MARCO, F, Benedetti, F, Vitolo, U, Patti, C, Rambaldi, A, Pulsoni, Alessandro, Musso, M, Liberati, Am, Olivieri, A, Gallamini, A, Pogliani, E, Scalabrini, Dr, Callea, V, DI RAIMONDO, F, Pavone, V, Tucci, A, Cortelazzo, S, Levis, A, Boccadoro, M, Majolino, I, Pileri, A, Gianni, Am, Passera, R, Corradini, P, Tarella, C, GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO GITMO, INTERGRUPPO ITALIANO LINFOMI IIL, Foa, Roberto, Ladetto, M, De Marco, F, Benedetti, F, Vitolo, U, Patti, C, Rambaldi, A, Pulsoni, A, Musso, M, Liberati, A, Olivieri, A, Gallamini, A, Pogliani, E, Scalabrini, D, Callea, V, Di Raimondo, F, Pavone, V, Tucci, A, Cortelazzo, S, Levis, A, Boccadoro, M, Majolino, I, Pileri, A, Gianni, A, Passera, R, Corradini, P, and Tarella, C

Subjects
Male, Lymphoma, Follicular lymphoma, Salvage therapy, PREDICTIVE MODEL, Kaplan-Meier Estimate, INDOLENT LYMPHOMA, CHOP, Biochemistry, Gastroenterology, Antibodies, Monoclonal, Murine-Derived, Risk Factors, MED/15 - MALATTIE DEL SANGUE, hemic and lymphatic diseases, BONE-MARROW-TRANSPLANTATION, TERM-FOLLOW-UP, DOSE SEQUENTIAL CHEMOTHERAPY, STEM-CELL TRANSPLANTATION, NON-HODGKINS-LYMPHOMA, PROGRESSION-FREE SURVIVAL, MINIMAL RESIDUAL DISEASE, UNTREATED PATIENTS, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Medicine, Prospective Studies, Treatment Failure, Lymphoma, Follicular, Antibodies, Monoclonal, Hematology, Middle Aged, Rituximab, prognosis, Transplantation, Autologou, Treatment Outcome, Female, Survival Analysi, Immunotherapy, medicine.drug, Human, Adult, medicine.medical_specialty, Adolescent, Immunology, Transplantation, Autologous, Chemoimmunotherapy, Internal medicine, Humans, Proportional Hazards Models, Salvage Therapy, Antineoplastic Combined Chemotherapy Protocol, business.industry, Risk Factor, Cell Biology, Phosphamide, medicine.disease, Survival Analysis, Surgery, Transplantation, Feasibility Studie, Prospective Studie, Proportional Hazards Model, Feasibility Studies, business
Abstract

In this randomized multicenter study of 136 patients, 6 courses of CHOP (cyclo-phosphamide/doxorubicin/vincristine/prednisone) followed by rituximab (CHOP-R) were compared with rituximab-supplemented high-dose sequential chemotherapy with autografting (R-HDS) to assess the value of intensified chemo-therapy as a first-line treatment for high-risk follicular lymphoma (FL) after the introduction of monoclonal antibodies. The analysis was intention to treat with event-free survival (EFS) as the primary endpoint. Complete remission (CR) was 62% with CHOP-R and 85% with R-HDS (P < .001). At a median follow-up (MFU) of 51 months, the 4-year EFS was 28% and 61%, respectively (P < .001), with no difference in overall survival (OS). Molecular remission (MR) was achieved in 44% of CHOP-R and 80% of R-HDS patients (P < .001), and was the strongest independent outcome predictor. Patients relapsing after CHOP-R underwent salvage R-HDS in 71% of cases. Salvage R-HDS had an 85% CR rate and a 68% 3-year EFS (MFU, 30 months). We conclude that (1) achieving MR is critical for effective disease control, regardless of which treatment is used; (2) R-HDS ensures superior disease control and molecular outcome than CHOP-R, but no OS improvement; and (3) CHOP-R failures have a good outcome after salvage R-HDS, suggesting that relapsed/refractory FL could be the most appropriate setting for R-HDS–like treatments. This trial was registered at www.clinicaltrials.gov as no. NCT00435955.

Published
2008

13. Update of a GITIL cohort study: Frontline high dose sequential chemotherapy with rituximab and autologous stem cell transplantation induces a high rate of long-term remissions in patients with mantle cell lymphoma

Author

Cortelazzo S, Magni M, Tarella C, Mian M, Billio A, Rossi A, Marchesi M, Gallamini A, Corradini P, Parvis G, Majolino I, Patti C, Mirto S, Benedetti F, Pizzolo G, Gianni AM, Rambaldi A., CICERI , FABIO, Cortelazzo, S, Magni, M, Tarella, C, Mian, M, Billio, A, Rossi, A, Marchesi, M, Gallamini, A, Corradini, P, Ciceri, Fabio, Parvis, G, Majolino, I, Patti, C, Mirto, S, Benedetti, F, Pizzolo, G, Gianni, Am, and Rambaldi, A.

Published
2007

14. The risk of secondary myelodysplastic syndrome/acute leukemia following intensive therapy and autograft correlates with the type of cells grafted: A survey on 1,347 lymphoma patients receiving the high-dose sequential (HDS) program

Author

Zanni M, Magni M, Rambaldi A, Benedetti F, Passera R, Patti C, Parvis G, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Boccadoro M, Saglio G, Pizzolo G, Barbui T, Gianni AM, Tarella C., CICERI , FABIO, Zanni, M, Magni, M, Rambaldi, A, Benedetti, F, Passera, R, Patti, C, Parvis, G, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Corradini, P, Boccadoro, M, Saglio, G, Pizzolo, G, Barbui, T, Gianni, Am, and Tarella, C.

Published
2007

15. Impact of complete remission achievement on the survival of lymphoma patients undergoing high-dose sequential chemotherapy and autograft (HDS programme): a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) retrospective study on 1,266 patients

Author

Tarella C, Zanni M, Rambaldi S, Magni M, Sorio M, Passera R, Patti C, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Boccadoro M, Corradini P, Benedetti F, Barbui T, Gianni AM, CICERI , FABIO, Tarella, C, Zanni, M, Rambaldi, S, Magni, M, Sorio, M, Passera, R, Patti, C, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Boccadoro, M, Corradini, P, Benedetti, F, Barbui, T, and Gianni, Am

Published
2007

16. Incidence and risk factors of secondary myelodysplastic syndromelacute leukemia occurrence following peripheral blood progenitor cell autograft: a GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) survey on 1266 lymphoma patients

Author

Zanni M, Magni M, Rambaldi A, Benedetti F, Rosato R, Passera R, Patti K, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Boccadoro M, Andreini A, Barbui T, Gianni AM, Tarella C., CICERI , FABIO, Zanni, M, Magni, M, Rambaldi, A, Benedetti, F, Rosato, R, Passera, R, Patti, K, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Corradini, P, Boccadoro, M, Andreini, A, Barbui, T, Gianni, Am, and Tarella, C.

Published
2007

17. Rituximab markedly improves the efficacy of high-dose programmes with autograft for B-cell lymphoma: a multicentre GITIL survey on 957 patients

Author

Tarella C, Zanni M, Magni M, Benedetti F, Barbui T, Boccadoro M, Patti C, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni AM, Rambaldi A., CICERI , FABIO, Tarella, C, Zanni, M, Magni, M, Benedetti, F, Barbui, T, Boccadoro, M, Patti, C, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Corradini, P, Passera, R, Pizzolo, G, Gianni, Am, and Rambaldi, A.

Published
2007

19. Prolonged survival of lymphoma patients achieving complete remission following high-dose sequential chemotherapy and autograft (HDS program): A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) retrospective study on 1,266 patients

Author

Tarella C, Zanni M, Rambaldi A, Magni M, Sorio M, Passera R, Patti C, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Boccadoro M, Corradini P, Benedetti F, Barbui T, Gianni AM, CICERI , FABIO, Tarella, C, Zanni, M, Rambaldi, A, Magni, M, Sorio, M, Passera, R, Patti, C, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Boccadoro, M, Corradini, P, Benedetti, F, Barbui, T, and Gianni, Am

Published
2006

20. Benefit of rituximab addition to high-dose programs with autograft for B-cell lymphoma: A multicenter GITIL survey on 957 patients

Author

Tarella C, Zanni M, Magni M, Benedetti F, Barbui T, Boccadoro M, Patti K, Gallamini A, Cortelazzo S, Zoli V, Mirto S, Passera R, Corradini P, Pizzolo G, Gianni AM, Rambaldi A., CICERI , FABIO, Tarella, C, Zanni, M, Magni, M, Benedetti, F, Barbui, T, Boccadoro, M, Patti, K, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Zoli, V, Mirto, S, Passera, R, Corradini, P, Pizzolo, G, Gianni, Am, and Rambaldi, A.

Published
2006

21. Splenic marginal zone lymphoma: A prognostic model for clinical use

Author

Arcaini, L, Lazzarino, M, Colombo, N, Burcheri, S, Boveri, E, Paulli, M, Morra, E, Gambacorta, M, Cortelazzo, S, Tucci, A, Ungari, M, Ambrosetti, A, Menestrina, F, Orsucci, L, Novero, D, Pulsoni, A, Frezzato, M, Gaidano, G, Vallisa, D, Minardi, V, Tripodo, C, Callea, V, Baldini, L, Merli, F, Federico, Massimo, Franco, V, Iannitto, E, INTEGRUPPO ITALIANO LINFOMI, Arcaini, L., Lazzarino, M., Colombo, N., Burcheri, S., Boveri, E., Paulli, M., Morra, E., Gambacorta, M., Cortelazzo, S., Tucci, A., Ungari, M., Ambrosetti, A., Menestrina, F., Orsucci, L., Novero, D., Pulsoni, A., Frezzato, M., Gaidano, G., Vallisa, D., Minardi, V., Tripodo, C., Callea, V., Baldini, L., Merli, F., Federico, M., Franco, V., and Iannitto, E.

Subjects
Male, splenic marginal zone lymphoma, prognostic factors, International Prognostic Index (IPI), VILLOUS LYMPHOCYTES, Hydro-Lyase, B-CELL, Longitudinal Studie, Predictive Value of Test, Biochemistry, Gastroenterology, Hemoglobins, chemistry.chemical_compound, International Prognostic Index, Risk Factors, BONE-MARROW INFILTRATION, NON-HODGKINS-LYMPHOMA, C VIRUS-INFECTION, Age Factor, Longitudinal Studies, Multivariate Analysi, Aged, 80 and over, Univariate analysis, Hematology, Mortality rate, Age Factors, Middle Aged, Prognosis, Splenic Neoplasm, Survival Rate, Predictive value of tests, Human, Adult, medicine.medical_specialty, Lymphoma, B-Cell, Prognosi, Immunology, Disease-Free Survival, Predictive Value of Tests, Albumins, Internal medicine, Lactate dehydrogenase, Aged, Humans, Hydro-Lyases, Multivariate Analysis, Platelet Count, Splenic Neoplasms, Models, Theoretical, medicine, Hemoglobin, Splenic marginal zone lymphoma, Survival rate, business.industry, Albumin, Risk Factor, Cell Biology, medicine.disease, Surgery, chemistry, business
Abstract

The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients. The 5-year cause-specific survival (CSS) rate was 76%. In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100 000/μL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006). Values that maintained a negative influence on CSS in multivariate analysis were hemoglobin level less than 12 g/dL, LDH level greater than normal, and albumin level less than 3.5 g/dL. Using these 3 variables, we grouped patients into 3 prognostic categories: low-risk group (41%) with no adverse factors, intermediate-risk group (34%) with one adverse factor, and high-risk group (25%) with 2 or 3 adverse factors. The 5-year CSS rate was 88% for the low-risk group, 73% for the intermediate-risk group, and 50% for the high-risk group. The cause-specific mortality rate (x 1000 person-years) was 20 for the low-risk group, 47 for the intermediate-risk group, and 174 for the high-risk group. This latter group accounted for 54% of all lymphoma-related deaths. In conclusion, with the use of readily available factors, this prognostic index may be an effective tool for evaluating the need for treatment and the intensity of therapy in an individual patient. © 2006 by The American Society of Hematology.

Published
2006

22. Incidence of secondary myelodysplastic syndrome/acute leukemia in 1,266 lymphoma patients following high-dose therapy and autograft: A study from GITIL (Gruppo italiano terapie innovative nei linfomi)

Author

Zanni M, Magni M, Rambaldi A, Benedetti F, Rosato R, Passera R, Patti C, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Boccadoro M, Andreini A, Barbui T, Gianni AM, Tarella C., CICERI , FABIO, Zanni, M, Magni, M, Rambaldi, A, Benedetti, F, Rosato, R, Passera, R, Patti, C, Ciceri, Fabio, Gallamini, A, Cortelazzo, S, Majolino, I, Mirto, S, Corradini, P, Boccadoro, M, Andreini, A, Barbui, T, Gianni, Am, and Tarella, C.

Published
2006

23. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma

Author

Ferreri, Andres J. M, Campo, E., Ambrosetti, A., Ilariucci, F., Seymour, J. F., Willemze, R., Arrigoni, G., Rossi, G., López Guillermo, A., Berti, E., Eriksson, M., Federico, M., Cortelazzo, S., Govi, S., Frungillo, N., Dell'Oro, S., Lestani, M., Asioli, S., Pedrinis, E., Ungari, M., Motta, T., Rossi, R., Artusi, T., Iuzzolino, P., Zucca, E., Cavalli, F., Ponzoni, M., Grisanti, S., Faccheti, F., Pavlovsky, M. A., Martelli, M., Geerts, M. L., Candoni, A., Piris, M. A., De Renzo, A., Milani, M., Ascani, Stefano, Pileri, S., Patriarca, C., Ferreri, A, Campo, E, Ambrosetti, A, Ilariucci, F, Seymour, J, Willemze, R, Arrigoni, G, Rossi, G, LOPEZ GUILLERMO, A, Berti, E, Eriksson, M, Federico, M, Cortelazzo, S, Govi, S, Frungillo, N, Dell'Oro, S, Lestani, M, Asioli, S, Pedrinis, E, Ungari, M, Motta, T, Rossi, R, Artusi, T, Izzulino, P, Zucca, E, Cavalli, F, Ponzoni, M, Ferreri, Ajm, Arnbrosetti, A, Seymour, Jf, Lopez Guillermo, A, Iuzzolino, P, and Ponzoni, Maurilio

Subjects
Oncology, Male, CHOP regimen, Cancer Research, Lymphoma, medicine.medical_treatment, angiotropic lymphoma, chemotherapy, CNS lymphoma, cutaneous lymphoma, intravascular lymphomatosis, intravascular lymphoma, Anthracycline, CHOP, 80 and over, adult, aged, anthracyclines, antineoplastic combined chemotherapy protocols, case-control studies, chop regimen, cns lymphoma, disease-free survival, female, humans, lymphoma, male, middle aged, patient selection, retrospective studies, vascular neoplasms, Autologous stem-cell transplantation, MED/35 - MALATTIE CUTANEE E VENEREE, Antineoplastic Combined Chemotherapy Protocols, Anthracyclines, Angiotropic lymphoma, Chemotherapy, Cutaneous lymphoma, Intravascular lymphomatosis, Adult, Aged, Aged, 80 and over, Case-Control Studies, Disease-Free Survival, Female, Humans, Middle Aged, Patient Selection, Retrospective Studies, Vascular Neoplasms, Hematology, Chemotherapy regimen, medicine.drug, medicine.medical_specialty, Vincristine, Cyclophosphamide, Internal medicine, medicine, business.industry, intravascular lymphoma, Anthracycline, chemotherapy, antracycline, intravascular lymphoma, Surgery, Transplantation, MED/06 - ONCOLOGIA MEDICA, business
Abstract

Background: Optimal therapeutic management of intravascular lymphoma (IVL) lacks precise guidelines. Patients and methods: The clinico-pathological features of 38 HIV-negative patients with IVL were reviewed to define efficacy of chemotherapy in these malignancies. Clinical characteristics of 22 patients treated with chemotherapy and of 16 untreated patients were compared in order to understand better the impact and causes of potential patient selection. Results: Median age was 70 years (range 34-90), with a male/female ratio of 0.9; 23 (61%) patients had Eastern Cooperative Oncology Group performance status (ECOG-PS) >1; 21 (55%) had systemic symptoms. Cutaneous lesions and anemia were significantly more common among patients treated with chemotherapy; central nervous system (CNS) and renal involvement were significantly more common among untreated patients. Chemotherapy was associated with a response rate of 59% and a 3-year overall survival of 33 ± 11%. Five of six patients with CNS involvement received chemotherapy: four of them died early; only one patient, treated with adriamycin, cyclophosphamide, vincristine, methotrexate, bleomycin and prednisolone (MACOP-B) followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), was alive at 19 months. High-dose chemotherapy supported by ASCT was indicated at diagnosis in another patient (43 years of age, stage I), who was alive at 71 months, and at relapse after cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in two patients who died early after transplantation. PS ≤1, disease limited to the skin, stage I, and use of chemotherapy were independently associated with better outcome. Conclusions: Anthracycline-based chemotherapy is the standard treatment for IVL. However, survival is disappointing, with a relevant impact of diagnostic delay and lethal complications. More intensive combinations, containing drugs with higher CNS bioavailability, are needed in cases with brain involvement, and the role of high-dose chemotherapy supported by ASCT should be further investigated in younger patients with unfavorable features. © 2004 European Society for Medical Oncology.

Published
2004

24. Cyclin D3 (CyD3) immunoreactivity (IR) is an independent predictor of survival and drives the correct assessment of p27 IR prognostic role in primary gastric lymphomas (PGL)

Author

Ponzoni, M., Giancarlo Pruneri, Ferreri, Ajm, Rognone, A., Freschi, M., Pozzi, B., Pinotti, G., Pigni, A., Cortelazzo, S., Motta, T., Devizzi, L., Andreola, S., Oro, S., Neri, A., Capella, C., Viale, G., Ponzoni, Maurilio, Pruneri, G, Ferreri, Ajm, Rognone, A, Freschi, M, Pozzi, B, Pinotti, G, Pigni, A, Cortelazzo, S, Motta, T, Devizzi, L, Andreola, S, Dell'Oro, S, Neri, A, Capella, C, and Viale, G.

Published
2003

25. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients

Author

Zinzani, Pl, Martelli, M, Bertini, M, Gianni, Am, Devizzi, L, Federico, M, Pangalis, G, Michels, J, Zucca, E, Cantonetti, M, Cortelazzo, S, Wotherspoon, A, Ferreri, Aj, Zaja, Francesco, Lauria, F, De Renzo, A, Liberati, Ma, Falini, B, Balzarotti, M, Calderoni, A, Zaccaria, A, Gentilini, P, Fattori, Pp, Pavone, E, Angelopoulou, Mk, Alinari, L, Brugiatelli, M, Di Renzo, N, Bonifazi, F, Pileri, Sa, Cavalli, F, International Extranodal Lymphoma Study Group, Zinzani, Pl, Martelli, M, Bertini, M, Gianni, Am, Devizzi, L, Federico, M, Pangalis, G, Michels, J, Zucca, E, Cantonetti, M, Cortelazzo, S, Wotherspoon, A, Ferreri, Aj, Zaja, Francesco, Lauria, F, De Renzo, A, Liberati, Ma, Falini, B, Balzarotti, M, Calderoni, A, Zaccaria, A, Gentilini, P, Fattori, Pp, Pavone, E, Angelopoulou, Mk, Alinari, L, Brugiatelli, M, Di Renzo, N, Bonifazi, F, Pileri, Sa, Cavalli, F, and International Extranodal Lymphoma Study, Group

Subjects
response rate, Author Keywords:PMLBCL, chemotherapy, radiotherapy, combined modality treatment KeyWords Plus:HIGH-DOSE CHEMOTHERAPY, NON-HODGKINS-LYMPHOMA, MACOP-B, COMBINATION CHEMOTHERAPY, MALIGNANT-LYMPHOMA, RADIATION-THERAPY, CLINICAL-TRIALS, TRANSPLANTATION, CLASSIFICATION, MANAGEMENT
Abstract

BACKGROUND AND OBJECTIVES: This multinational retrospective study compares the outcomes of patients with primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis after first-generation (dose-intensive regimens), third-generation (alternating regimens) and high-dose chemotherapy strategies, frequently with adjuvant radiation therapy. DESIGN AND METHODS: Between August 1981 and December 1999, a total of 426 previously untreated patients with confirmed diagnosis were enrolled in 20 institutions to receive combination chemotherapy with either first generation (CHOP or CHOP-like) regimens, third generation (MACOP-B, VACOP-B, ProMACE CytaBOM) regimens or high-dose chemotherapy (HDS/ABMT). RESULTS: With chemotherapy, complete response (CR) rates were 49% (50/105), 51% (142/277) and 53% (23/44) with first generation, third generation and high-dose chemotherapy strategies, respectively; partial response (PR) rates were 32%, 36% and 35%, respectively. All patients who achieved CR and 124/142 (84%) with PR had radiation therapy on the mediastinum. The final CR rates became 61% for CHOP/CHOP-like regimens, 79% for MACOP-B and other regimens, and 75% for HDS/ABMT. After median follow-ups from attaining CR of 48.5 months for CHOP/CHOP-like regimens, 51.7 months for MACOP-B type regimens and 32.4 months for HDS/ABMT, relapses occurred in 15/64 (23%), 27/218 (12%) and 0/33 (0%) patients, respectively. Projected 10-year progression-free survival rates were 35%, 67% and 78%, respectively (p=0.0000). Projected 10-year overall survival rates were 44%, 71% and 77%, respectively (p=0.0000), after median follow-ups from diagnosis of 52.3 months, 54.9 months and 35.8 months, respectively. INTERPRETATION AND CONCLUSIONS: In patients with PMLBCL with sclerosis, MACOP-B plus radiation therapy may be a better strategy than other treatments; these retrospective data need to be confirmed by prospective studies. The encouraging survival results after high dose chemotherapy require confirmation in selected high-risk patients.

Published
2002

26. Prognostic scoring system for Primary Central Nervous System Lymphomas: the IELSG proposal

Author

Ferreri AJM, Blay J-Y, Calderoni A, Ambrosetti A, Tirelli U, Cortelazzo S, Gubkin A, Zucca E, Gomez H, Orvieto E, Borish B, Berger F, Jouvet A, Tingueli M, Chassagne C, Ponzoni M, Reni M, Ferreri, Ajm, Blay, J-Y, Calderoni, A, Ambrosetti, A, Tirelli, U, Cortelazzo, S, Gubkin, A, Zucca, E, Gomez, H, Orvieto, E, Borish, B, Berger, F, Jouvet, A, Tingueli, M, Chassagne, C, Ponzoni, M, and Reni, M

Published
2001

27. Post-transplant lymphoproliferative disease of donor origin, following haematopoietic stem cell transplantation in a patient with blastic plasmacytoid dendritic cell neoplasm

Author

Piccin, A, Morello, E, Svaldi, M, Haferlach, T, Facchetti, Fabio, Negri, G, Vecchiato, C, Fisogni, S, Pusceddu, I, and Cortelazzo, S.

Subjects
Adult, Male, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Skin Neoplasms, Remission Induction, Hematopoietic Stem Cell Transplantation, Dendritic Cells, Prognosis, Lymphoproliferative Disorders, Hematologic Neoplasms, Humans, Transplantation, Homologous, Female, Neoplasms, Plasma Cell
Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare condition that originates from dendritic cells. We report on the first case of Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disorder (PTLD) of donor origin in a BPDC patient post-allogeneic haematopoietic stem cell transplantation (HSCT). Flow cytometry study identified a cell population CD4+/CD56+/CD45RA+/CD123+/TCL1+ suggestive of BPDCN diagnosis, which was confirmed by a lymph node biopsy (cells positive for BCL11a, BDCA-2, CD2AP, CD123, TCL1 and S100). Cytogenetic analysis revealed a complex karyotype: (19 metaphase) 47,XX,t(1;6)(q21;q2?5),-13 + 2mar[11]/47, XX, +21 [3]/46,XX [5]. The patient was started on acute myeloid leukaemia (AML) induction schedule, and subsequently an allogeneic HSCT was performed. On day +36 post-HSCT, bone marrow biopsy/aspirate showed complete morphological remission, and chimerism study showed 100% donor chimera. However, on day +37, the patient was found to have enlarged cervical and supraclavicular lymphoadenopathy, splenomegaly and raised lactic dehydrogenase. EBV-DNA copies in blood were elevated, consistent with a lytic cycle. A lymph node biopsy showed EBV encoded RNA and large atypical B cells (CD45dim-, CD4+/CD56+, monoclonal for k-chain, CD19+/CD20+/CD21+/CD22+/CD38+/CD43+/CD79β-/CD5-/CD10-), consistent with PTLD monomorphic type. Chimerism study showed that PTLD was of donor origin. This case together with the recent literature findings on BPDCN and PTLD are discussed.

Published
2012

30. Safety and Efficacy of Bendamustine With Or Without Rituximab In the Treatment of Heavily Pretreated Lymphoma Patients. A Multicenter Retrospective Study

Author

Rigacci, L., Iannitto, E., Puccini, B., Antognoli, G., D'Arco, A., Orciuolo, E., Cortelazzo, S., Gaidano, G., Freilone, R., Patti, C., Zaja, F., Gobbi, M., Musto, P., Zinzani, P. L., Storti, S., Isidori, A., Bongarzoni, V., Carpaneto, A., Renzo, N. D., Musso, M., Scalabrini, D. R., Santagostino, A., Stelitano, C., Cascavilla, N., Liberati, Anna Marina, Sancetta, R., and Bosi, A.

Published
2010

32. Long-term Outcome of 309 Young Patients With Untreated Diffuse Large B-cell Lymphoma (dlbcl) At Poor Prognosis: A Pooled Analysis From Gimurell and Intergruppo Italiano Linfomi (iil)

Author

ANNALISA CHIAPPELLA, Cabras, M. G., Liberati, A. M., Angelucci, E., Baldini, L., Bottelli, C., Botto, B., Cascavilla, N., Ciccone, G., Cortelazzo, S., Masi, P., Falchi, L., Fioritoni, G., Frairia, C., Freilone, R., Levis, A., Orsucci, L., Parvis, C., Pogliani, E., Rota-Scalabrini, D., Salvi, F., Specchia, G., Tonso, A., Tucci, A., and Vitolo, U.

Published
2010

33. PROSPECTIVE, MULTICENTER RANDOMIZED GITMO/IIL TRIAL COMPARING INTENSIVE (R-HDS) VERSUS CONVENTIONAL CHEMOIMMUNOTHERAPY (CHOP-R) IN HIGH-RISK FOLLICULAR LYMPHOMA AT DIAGNOSIS: THE HIGHER MOLECULAR REMISSION RATE OF R-HDS ACCOUNTS FOR ITS SUPERIOR CLINICAL PERFORMANCE

Author

Ladetto, M., M. F., De, Benedetti, F., Vitolo, U., Patti, C., Rambaldi, A., Pulsoni, A., Musso, M., Liberati, Anna Marina, Olivieri, A., Gallamini, A., Pogliani, E., Scalabrini, D. R., Callea, V., Raimondo, F. D., Pavone, V., Tucci, A., Cortelazzo, S., Levis, A., Boccadoro, M., Majolino, I., Pileri, A., Gianni, A. M., Passera, R., Corradini, P., and Tarella, C.

Published
2007

34. Final results of phase II gimurell trial: The addition of Rituximab to dose-dense and high dose chemotherapy (HDC) with autologous transplantation (ASCT) improves the outcome of untreated poor-prognosis diffuse large B-cell lymphoma (DLBCL)

Author

ANNALISA CHIAPPELLA, Liberati, A. M., Rossi, G., Cabras, M. G., Levis, A., Pavone, V., Angelucci, E., Botto, B., Ciccone, G., Cortelazzo, S., Falchi, L., Freilone, R., Gaidano, G., Novero, D., Pogliani, E. M., Pregno, P., Rota Scalabrini, D., Salvi, F., Tonso, A., Tucci, A., Gallo, E., and Vitolo, U.

Published
2007

36. PROSPECTIVE, MULTICENTER RANDOMIZED GITMO/IIL TRIAL COMPARING INTENSIVE (R-HDS) VERSUS CONVENTIONAL CHEMOIMMUNOTHERAPY (CHOP-R) IN HIGH-RISK FOLLICULAR LYMPHOMA AT DIAGNOSIS: THE SUPERIOR MOLECULAR REMISSION (MR) RATE OF R-HDS EXPLAINS ITS BETTER CLINICAL PERFORMANCE

Author

Ladetto, M., DE MARCO, F., Benedetti, F., Vitolo, U., Patti, C., Rambaldi, A., Pulsoni, A., Musso, M., Liberati, A. M., Olivieri, A., Gallamini, A., Pogliani, E., ROTA SCALABRINI, D., Callea, V., DI RAIMONDO, Francesco, Pavone, V., Tucci, A., Cortelazzo, S., Levis, A., Boccadoro, M., Majolino, I., Pileri, A., Gianni, A. M., Passera, R., Corradini, P., and Tarella, C.

Published
2007

37. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional chemoimmunotherapy (CHOP-R) in high-risk follicular lymphoma at diagnosis: The superior molecular remission (MR) rate of R-HDS explains its better clinical performance

Author

Ladetto, M., Marco, F. D., Benedetti, F., Vitolo, U., Patti, C., Rambaldi, A., Pulsoni, A., Musso, M., Liberati, Anna Marina, Olivieri, A., Gallamini, A., Pogliani, E., Scalabrini, D. R., Callea, V., Raimondo, F. D., Pavone, V., Tucci, A., Cortelazzo, S., Levis, A., Boccadoro, M., Majolino, I., Pileri, A., Gianni, A. M., Passera, R., Corradini, P., and Tarella, C.

Published
2007

46. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue

Author

Zucca, E, Conconi, A, Pedrinis, E, Cortelazzo, S, Motta, T, Gospodarowicz, Mk, Patterson, Bj, Ferreri, Aj, Ponzoni, M, Devizzi, L, Giardini, R, Pinotti, G, Capella, CARLO RENATO, Zinzani, Pl, Pileri, S, LOPEZ GUILLERMO, A, Campo, E, Ambrosetti, A, Baldini, L, Cavalli, F, and INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP

Published
2003

47. Patterns of outcome and prognostic factors in primary large cell lymphoma of the testis in a survey of 373 patients by the International Extranodal Lymphoma Study Grfoup (IELSG)

Author

Zucca, E, Conconi, A, Mughal, Ti, Sarris, Ah, Seymour, Jf, Vitolo, U, Klasa, R, Ozsahin, M, Mead, Gm, Gianni, Ma, Cortelazzo, S, Ferreri, Ajm, Ambrosetti, Achille, Martelli, M, Thieblemont, C, GOMEZ MORENO, H, Pinotti, G, Martinelli, G, Mozzana, R, Grisanti, S, Provencio, M, Balzarotti, M, Laveder, F, Oltean, G, Callea, V, Roy, P, Cavalli, F, and Gospodarowicz, Mk

Subjects
Diffuse large B-cell lymphoma, testis, Diffuse large B-cell lymphoma, testis
Published
2003

48. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma

Author

Gianni, A. M., Cortelazzo, S., Magni, M., Martelli, Maurizio, and Michelangelo, Cooperative

Subjects
Oncology, Melphalan, medicine.medical_specialty, MINIMAL RESIDUAL DISEASE, Pilot Projects, Lymphoma, Mantle-Cell, Antibodies, Monoclonal, Murine-Derived, Autologous stem-cell transplantation, HIGH-DOSE CHEMOTHERAPY, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Transplantation, business.industry, Bone Marrow Purging, Remission Induction, NON-HODGKINS-LYMPHOMAS, Antibodies, Monoclonal, Hematology, HIGH-DOSE CHEMOTHERAPY, POLYMERASE CHAIN-REACTION, MINIMAL RESIDUAL DISEASE, NON-HODGKINS-LYMPHOMAS, POLYMERASE CHAIN-REACTION, medicine.disease, Chemotherapy regimen, Bone marrow purging, Surgery, Regimen, Mantle cell lymphoma, Rituximab, business, Stem Cell Transplantation, medicine.drug
Abstract

Mantle cell lymphoma (MCL) responds poorly to standard chemotherapy regimens used in non-Hodgkin's lymphoma. As a result, a combination of high-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) is being investigated in patients with MCL. So far, however, there is no evidence for long-term remission -- believed, in part, to be due to contamination of the transfusion product with residual cancer cells. Many ex-vivo purging methods have been developed to remove tumour cells, but these are complicated, time-consuming and expensive. This study describes an in vivo purging method using rituximab to produce a tumour-free stem cell product for re-infusion following HDT. The regimen is split into a purging phase and a myeloablative phase, which together consist of four-step high-dose sequential chemotherapy (sHDT) and six infusions of rituximab immunotherapy. The sHDT comprises cyclophosphamide, cytosine arabinoside, melphalan and mitoxantrone plus melphalan. There are two separate stem cell harvests and three reinfusions. In a pilot study 28 patients with untreated MCL received standard chemotherapy followed by sHDT with rituximab in vivo purging. Preliminary results indicate that in PCR analyses of leukaphereses from 20 assessable patients, 100% lymphoma-negative harvests were achieved following in vivo purging. PCR analyses of the bone marrow following the four-step high-dose regimen with purging and transplantation showed that all patients achieved molecular remission. After a median follow-up of 22 months (range 10-42 months), two patients had died while 26 were alive and disease free. This method allows efficient in vivo purging in the context of an effective chemotherapy regimen and may have a role as first-line therapy in MCL patients who respond poorly to standard treatment.

Published
2002

49. Induction chemotherapy stategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients

Author

Pl, Zinzani, Martelli M, Bertini M, Am, Gianni, Devizzi L, Federico M, Pangalis G, Michels J, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon A, Aj, Ferreri, Zaja F, Lauria F, De Renzo A, Ma, Liberati, Falini B, Balzarotti M, and Calderoni A

Subjects
PMLBCL, chemotherapy, radiotherapy, response rate, combined modality treatment
Published
2002

50. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma

Author

Cortelazzo, S, Rambaldi, A, Rossi, A, Oldani, E, Ghielmini, M, Benedetti, F, Tarella, Corrado, Zaglio, F, Vitolo, U, DI NICOLA, M, Pogliani, E, Cavalli, F, Gianni, Am, and Barbui, T.

Subjects
Adult, Male, Salvage Therapy, Adolescent, Lymphoma, Non-Hodgkin, Hematopoietic Stem Cell Transplantation, Middle Aged, Transplantation, Autologous, Disease-Free Survival, Drug Administration Schedule, Survival Rate, Methotrexate, Recurrence, Antineoplastic Combined Chemotherapy Protocols, Humans, Regression Analysis, Female, Cyclophosphamide, Aged, Etoposide, Retrospective Studies
Abstract

The aim of the present study was to retrospectively evaluate whether a high-dose sequential chemotherapy programme (HDS: cyclophosphamide, methotrexate, etoposide) administered prior to autologous transplantation could optimize the salvage of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Between 1985 and 1999, 103 patients (median age 43 years, range 16-65) from eight Italian centres and one Swiss centre, with refractory (n = 38) or relapsed (n = 65) diffuse large B-cell and T-cell lymphoma, were treated using HDS followed by high-dose regimens with autologous haematopoietic stem cell transplantation. Eighty-three patients responded to the HDS regimen (81%, 95% C.I., 73- 88%) and 79 eventually achieved a complete response (CR) after autotransplantation (90%, 95% C.I., 81- 96%). None of 20 cases resistant to HDS attained CR. Treatment-related mortality was 4%. After a median follow-up of 24 months (range 6-174 months), 3-year estimates of overall survival, event-free survival and disease-free survival were 47% (95% C.I., 36-59%), 44% (95% C.I., 34-54%) and 64% (95% C.I., 50-74%) respectively. Multivariate analysis showed that chemosensitivity to HDS represented the strongest predictor of both CR and survival. This retrospective study shows that salvage treatment using HDS had relatively low toxicity and was associated with remarkable response rates, allowing further effective therapy with high-dose autograft programmes.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results